Michael Barbella, Managing Editor04.17.23
Nextkidney has raised €11.9 million in a recent B funding round. The round combined a €7.8 million investment by professional and informal investors in France and The Netherlands with a crowdfunding campaign (led by OnePlanetCrowd) that raked in €4.1 million.
The funds will be used for clinical trials and market clearance of the company's portable kidney failure treatment device.
Kidney failure treatment is a growing issue in public health policies. It is one of the main sources of healthcare costs in Western societies with more than $40 billion spent in 2020 in the United States alone. Worldwide, the number of kidney patients dependent on dialysis expands by 6% annually.
"The continued growth of the global dialysis market demands for a device that addresses current issues of manpower, logistics and patients' quality of life," Nextkidney CEO Jérôme Augustin said. "The Neokidney does this by enabling patients to perform dialysis treatments any place at any time, not hampered by logistics of fluids or infrastructure, enabling patients to longer stay connected to society and their professional lives."
The Neokidney's design enhances patients' dialysis experience with a simple to use interface and minimal footprint in patients' homes. Its sorbent technology drastically reduces fluid usage and power consumption, providing dialysis therapy outcomes that are on par with those of state-of-the-art home hemodialysis devices.
"We are thrilled to have raised this significant amount of funding, which will allow us to bring our innovative device through clinical trials and market clearance," Nextkidney Chief Financial Officer John Stooker stated. "Our goal is to improve the lives of kidney failure patients by offering them a solution that is both effective and convenient, and we believe that our device will do more than just that."
Nextkidney's crowd funding campaign garnered strong interest from healthcare providers and patients internationally who eagerly anticipate the Neokidney's launch.
Nextkidney's is developing the Neokidney home hemodialysis device. The company places the patient and his/her quality of life at the centre of its approach and uses innovative technologies to offer a safe, practical, and easy-to-use solution. The Neokidney is a registered trademark of NextKidney S.A.
The funds will be used for clinical trials and market clearance of the company's portable kidney failure treatment device.
Kidney failure treatment is a growing issue in public health policies. It is one of the main sources of healthcare costs in Western societies with more than $40 billion spent in 2020 in the United States alone. Worldwide, the number of kidney patients dependent on dialysis expands by 6% annually.
"The continued growth of the global dialysis market demands for a device that addresses current issues of manpower, logistics and patients' quality of life," Nextkidney CEO Jérôme Augustin said. "The Neokidney does this by enabling patients to perform dialysis treatments any place at any time, not hampered by logistics of fluids or infrastructure, enabling patients to longer stay connected to society and their professional lives."
The Neokidney's design enhances patients' dialysis experience with a simple to use interface and minimal footprint in patients' homes. Its sorbent technology drastically reduces fluid usage and power consumption, providing dialysis therapy outcomes that are on par with those of state-of-the-art home hemodialysis devices.
"We are thrilled to have raised this significant amount of funding, which will allow us to bring our innovative device through clinical trials and market clearance," Nextkidney Chief Financial Officer John Stooker stated. "Our goal is to improve the lives of kidney failure patients by offering them a solution that is both effective and convenient, and we believe that our device will do more than just that."
Nextkidney's crowd funding campaign garnered strong interest from healthcare providers and patients internationally who eagerly anticipate the Neokidney's launch.
Nextkidney's is developing the Neokidney home hemodialysis device. The company places the patient and his/her quality of life at the centre of its approach and uses innovative technologies to offer a safe, practical, and easy-to-use solution. The Neokidney is a registered trademark of NextKidney S.A.